Oncodesign S.A.
Records under this name other than the patents Oncodesign S.A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
Showing 1 to 8 of 8 · Back to Oncodesign S.A.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,676,486 | Macrocyclic RIP2 kinase inhibitors Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,716,869 | Radiolabeled Macrocyclic Egfr Inhibitor Formerly held In force · High confidence | In force | High confidence | |
| US 10,377,772 | Macrocyclic LRRK2 kinase inhibitors Lapsed on the fee record Ended Aug 13, 2023 · From the USPTO record | Lapsed on the fee record | Ended Aug 13, 2023 | From the USPTO record |
| US 9,586,975 | Macrocyclic salt-inducible kinase inhibitors Lapsed on the fee record Ended Mar 7, 2021 · From the USPTO record | Lapsed on the fee record | Ended Mar 7, 2021 | From the USPTO record |
| US 9,370,519 | Macrocyclic FLT3 kinase inhibitors Lapsed on the fee record Ended Jun 21, 2020 · From the USPTO record | Lapsed on the fee record | Ended Jun 21, 2020 | From the USPTO record |
| US 9,370,520 | Macrocyclic LRRK2 kinase inhibitors Lapsed on the fee record Ended Jun 21, 2020 · From the USPTO record | Lapsed on the fee record | Ended Jun 21, 2020 | From the USPTO record |
| US 9,096,609 | Macrocyclic LRRK2 kinase inhibitors Lapsed on the fee record Ended Aug 4, 2019 · From the USPTO record | Lapsed on the fee record | Ended Aug 4, 2019 | From the USPTO record |
| US 9,090,630 | Macrocyclic FLT3 kinase inhibitors Lapsed on the fee record Ended Jul 28, 2019 · From the USPTO record | Lapsed on the fee record | Ended Jul 28, 2019 | From the USPTO record |